Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
BJU Int. 2013 Aug;112(3):407-15. doi: 10.1111/j.1464-410X.2012.11653.x. Epub 2013 Mar 7.
WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The current basis for diagnosis and prognosis in urinary bladder cancer is based on the pathologists' assessment of a biopsy of the tumour. Urinary biomarkers are preferable as they can be non-invasively sampled. Urinary cytology is the only test with widespread use but is hampered by poor reproducibility and low sensitivity. By studying the protein expression in bladder tumour tissue samples of proteins previously found in elevated levels in the urine of patients with bladder cancer, we have been able to show that these proteins originate from the tumour. The immunoreactivity of three of the investigated proteins increased with higher stage. Also a serine peptidase inhibitor was found to be predictive of progression from non-muscle-invasive to muscle-invasive tumours.
To analyse the expression of five bladder cancer-associated urinary proteins and investigate if expression is related to the malignant phenotype of the tumour. To explore the possible prognostic value of these proteins.
Urine samples, 16 from patients with bladder cancer and 26 from controls, were used in Western Blotting experiments. Tissue microarrays with bladder tissue from 344 patients diagnosed with bladder cancer between 1984 and 2005 was used in immunohistochemistry experiments. The proteins apolipoprotein E (APOE), fibrinogen β chain precursor (FGB), leucine-rich α2-glycoprotein (LRG1), polymerase (RNA) I polypeptide E (POLR1E), α1-antitrypsin (SERPINA1) and topoisomerase 2A (TOP2A) were probed with antibodies validated by the Human Protein Atlas.
Increased expressions of APOE, FGB and POLR1E were correlated with increased tumour stage (P < 0.001). Expression of SERPINA1 in Ta and T1 tumours was found to increase the risk of tumour progression (hazard ratio 2.57, 95% confidence interval 1.13-5.87; P = 0.025) CONCLUSIONS: All proteins previously detected in urine from patients with bladder cancer were also expressed in bladder cancer tissue. The expression of APOE, FGB and POLR1E increased with stage and they are potential diagnostic markers. SERPINA1 was identified as a prognostic marker candidate.
分析五种膀胱癌相关尿蛋白的表达情况,并探讨其表达与肿瘤恶性表型的关系。探索这些蛋白的可能预后价值。
使用 Western Blotting 实验检测了 16 例膀胱癌患者和 26 例对照者的尿液样本。使用免疫组织化学实验检测了 344 例 1984 年至 2005 年间诊断为膀胱癌的患者的组织微阵列中的膀胱组织。用经人蛋白图谱验证的抗体探测载脂蛋白 E(APOE)、纤维蛋白原β链前体(FGB)、富含亮氨酸的α2-糖蛋白(LRG1)、聚合酶(RNA)I 多肽 E(POLR1E)、α1-抗胰蛋白酶(SERPINA1)和拓扑异构酶 2A(TOP2A)这 5 种蛋白。
APOE、FGB 和 POLR1E 的表达增加与肿瘤分期增加相关(P<0.001)。Ta 和 T1 肿瘤中 SERPINA1 的表达被发现增加了肿瘤进展的风险(危险比 2.57,95%置信区间 1.13-5.87;P=0.025)。
先前在膀胱癌患者尿液中检测到的所有蛋白在膀胱癌组织中也有表达。APOE、FGB 和 POLR1E 的表达随分期增加而增加,它们是潜在的诊断标志物。SERPINA1 被确定为候选预后标志物。